Brainstorm Cell Therapeutics agrees to settle shareholder derivative litigation over alleged misleading statements

PUBT · 15h ago
Brainstorm Cell Therapeutics agrees to settle shareholder derivative litigation over alleged misleading statements
  • Brainstorm Cell Therapeutics agreed to settle shareholder derivative litigation through corporate governance reforms lasting at least four years, subject to court approval.
  • Defendants' insurers will pay $725,000 in plaintiffs' attorneys' fees and expenses, subject to court approval.
  • Plaintiffs allege fiduciary breaches involving misleading disclosures about NurOwn's FDA setbacks, manufacturing deficiencies and safety risks; defendants deny wrongdoing.
  • A federal court hearing on the proposed settlement is scheduled for January 5, 2027, at 10:00 a.m. in New York.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611201700PRIMZONEFULLFEED9881686) on November 20, 2026, and is solely responsible for the information contained therein.